Abstract 5959
Background
Early loco-regional failure (LRF) after organ preservation therapy (OPT) varies widely for hypopharyngeal squamous cell carcinoma (HPSCC) patients. We aim to develop and validate a MRI-derived radiomic signature RS for the prediction of 1-year LRF in HPSCC treated with OPT, and investigate its efficacy between OPT and total laryngectomy (TL) cohort.
Methods
A total of 3912 MRI-based radiomic features (RF) of pretreatment tumors were obtained from 370 HPSCC patients, including OPT cohort1 (OPT1; n = 186), OPT cohort2 (OPT2; n = 88), and TL cohort (TLc; n = 96). Variational autoencoder (VAE), trained with symmetric two encoded and decoded layers of neural network was applied to reduce the dimensionality of original RF to 128 VAE-RF. Least absolute shrinkage and selection operator with 10-fold cross validation performs features selection and constructs RS to predict 1-year LRF events in OPT1, which was validated in OPT2 and TLC. Harrell’s C-index was used to evaluate the discriminative ability of RS. Optimal cut-point for dichotomized RS risk category was determined via Youden index. Pair-wise propensity score matching (caliper 0.2) using pre-treatment variables (age, gender, TNM stage) was applied to compare the impact of OPT and TL under different RS risk categories.
Results
The RS yielded 1000 times bootstrapping corrected C-index of 0.753, 0.745 and 0.398 in the OPT1, OPT2 and TLC, respectively. Dichotomized risk category using Youden cut-point of RS yielded 1 year LRF predictive accuracy of 71.12%, 70.41%, and 41.74% in OPT1, OPT2 and TLC, respectively. In RS-high risk group, OPT were associated with poor progression-free survival (PFS, HR: 1.752, p = 0.032), while in RS-low risk group, OPT did not deteriorate the PFS (HR: 0.774, p = 0.416).
Conclusions
The RS-based model provides a novel to predict 1-year LRF and survival in patients with HPSCC who received OPT. The prediction performance discrepancy of MRI-derived RS in TLC also emphasizes the role of TL in RS-high risk group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3107 - Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: a large multicentric database analysis
Presenter: Paolo Bossi
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2016 - High Immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
Presenter: Haitham Mirghani
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2603 - Analysis of Efficacy Outcomes Based on Programmed Death Ligand 1 (PD-L1) Scoring Techniques in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) From KEYNOTE-040
Presenter: Ezra Cohen
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
4782 - A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): safety, clinical, and correlative outcomes
Presenter: Adam Luginbuhl
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
2557 - Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
Presenter: Siddharth Sheth
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
4934 - Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): safety phase of randomized trial GORTEC 2017-01 (REACH)
Presenter: Yungan Tao
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
4541 - Inducible T cell Costimulatory (ICOS) Receptor Agonist, GSK3359609 (GSK609) alone and in combination with Pembrolizumab (pembro): preliminary results from INDUCE-1 expansion cohorts (EC) in Head and Neck Squamous Cell Carcinoma (HNSCC)
Presenter: Danny Rischin
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
3463 - Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: a phase II multicenter trial
Presenter: Jérome Fayette
Session: Poster Discussion – Head and neck cancer
Resources:
Abstract
Poster Discussion – Head and neck cancer - Invited Discussant 1112PD, 1113PD and 1114PD
Presenter: Laura Locati
Session: Poster Discussion – Head and neck cancer
Resources:
Slides
Webcast
Poster Discussion – Head and neck cancer - Invited Discussant 1115PD, 1116PD, 1117PD and 1118PD
Presenter: Jean-Pascal Machiels
Session: Poster Discussion – Head and neck cancer
Resources:
Slides
Webcast